BDB-001

韦洛利单抗(舒泰神)

Report date: 2025/11/06 17:40:04

Base Information

Drug NameBDB-001
Drug Alias NameBDB-001注射液BDB-001BDB001BDB 001BDB-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionComplement C5a inhibitors
TargetsComplement C5a
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisVasculitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBangladeshSpainIndia +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesStaidson(Beijing) Biopharmaceuticals Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Defengrui Biotechnology Co LtdStaidson(Beijing) Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisVasculitisHidradenitis Suppurativa
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A
Related LinksN/A